8-Bromo-cGMP sodium is a membrane-permeable analog of cGMP and acts as a PKG activator; it significantly inhibits Ca²⁺ macroscopic currents and impairs high K⁺-stimulated insulin release; exhibits analgesic and vasodilatory effects; increases resistance of LLC-PK1 cells to cyclosporin A (CsA) toxicity in a concentration-dependent manner; induces heme oxygenase-1 (HO-1) protein synthesis in a concentration-dependent fashion; dose-dependently increases tail-flick latency in vincristine-treated mice, demonstrating antinociceptive activity; elicits vasodilator responses in both eNOS-Tg mice and wild-type littermates.